Surgical management of pancreatic neuroendocrine tumors: an introduction.
Elisabeth HainRémy SindayigayaJade FawazJoseph GhariosGaspard BouteloupPhilippe SoyerJérôme BertheratFrédéric PratBenoit TerrisRomain CoriatSébastien GaujouxPublished in: Expert review of anticancer therapy (2019)
Introduction: Neuroendocrine tumors of the pancreas (pNETs) represent only 1% to 2% of all pancreatic neoplasms. These tumors can be classified as functional or nonfunctional tumors; as sporadic or from a genetic origin; as neuroendocrine neoplasms or carcinoma. Over the last decade, diagnosis of pNETs has increased significantly mainly due to the widespread use of cross-sectional imaging. Those tumors are usually associated with a good prognosis. Surgery, the only curative option for those patients, should always be discussed, ideally in a multidisciplinary team setting.Areas covered: We discuss i), the preoperative management of pNETs and the importance of accurate diagnosis, localization, grading and staging with computed tomography, magnetic resonance imaging, endoscopic ultrasound, and nuclear medicine imaging; ii), surgical indications and iii), the surgical approach (standard pancreatectomy vs pancreatic-sparing surgery).Expert opinion: The treatment option of all patients presenting with pNETs should be discussed in a multidisciplinary team setting with surgeon's experienced in both pancreatic surgery and neuroendocrine tumor management. A complete preoperative imaging assessment - morphological and functional - must be performed. Surgery is usually recommended for functional pNETs, nonfunctional pNETs >2 cm (nf-pNETs) or for symptomatic nf-pNETs.
Keyphrases
- neuroendocrine tumors
- minimally invasive
- magnetic resonance imaging
- coronary artery bypass
- high resolution
- computed tomography
- cross sectional
- surgical site infection
- signaling pathway
- palliative care
- quality improvement
- oxidative stress
- patients undergoing
- prognostic factors
- lymph node
- robot assisted
- lps induced
- nuclear factor
- ejection fraction
- late onset
- gene expression
- clinical practice
- newly diagnosed
- dna methylation
- pet ct
- inflammatory response
- genome wide
- photodynamic therapy
- patient reported outcomes
- smoking cessation
- image quality
- amyotrophic lateral sclerosis